Johnson & Johnson's CAPLYTA® Approved by FDA for Major Depressive Disorder Treatment

Key highlights
  • FDA approved CAPLYTA\u00ae for major depressive disorder as an adjunctive therapy.
  • CAPLYTA\u00ae showed significant improvement in depression symptoms in Phase 3 trials.
  • The trials demonstrated a large separation in MADRS scores between CAPLYTA\u00ae and placebo.
  • CAPLYTA\u00ae does not require dose titration and has a safety profile similar to placebo.

FDA Approval

The FDA has approved CAPLYTA® (lumateperone) as an adjunctive therapy with antidepressants for treating major depressive disorder (MDD) in adults. This marks the first approval under Johnson & Johnson's leadership following its acquisition of Intra-Cellular Therapies, Inc.

Clinical Trials

The approval is based on positive results from two Phase 3, double-blind, placebo-controlled trials, Studies 501 and 502. Both studies met their primary and key secondary endpoints, showing statistically significant and clinically meaningful improvement in depression symptoms compared to an oral antidepressant plus placebo.

Trial Results

In Study 501, a large separation in total MADRS score was observed between CAPLYTA® and placebo (-4.9 points, effect size 0.61), and in Study 502 (-4.5 points, effect size 0.56) at six weeks. Separation from placebo was seen as early as one week in Study 501 and two weeks in Study 502.

Safety Profile

CAPLYTA®'s safety profile was consistent with existing data for its schizophrenia and bipolar depression indications. No new safety concerns were identified, and weight gain and metabolic changes were similar to placebo. Common side effects include sleepiness, dizziness, nausea, dry mouth, feeling tired, and diarrhea.

Long-term Data

Long-term data from the 503 open-label extension safety study showed CAPLYTA® was safe and well-tolerated, with 80% of patients responding to treatment and 65% experiencing remission at six months.

Source: J&J

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

4 May 2026
Johnson & Johnson: CAPLYTA tops adjunctive MDD antipsychotics in network meta-analysis

Network meta-analysis of 10 trials found an adjunctive atypical antipsychotic superior on MADRS change, response, remission and CGI‑S, with no significant weight gain and favorable tolerability.

27 April 2026
Johnson & Johnson: FDA approves CAPLYTA sNDA to reduce schizophrenia relapse risk

FDA approved sNDA for CAPLYTA (lumateperone) to prevent relapse in schizophrenia. Phase 3 randomized‑withdrawal: 63% lower relapse risk (HR 0.37); 84% relapse‑free at 6 months; safety consistent.

19 November 2026
Johnson & Johnson files for CAPLYTA approval in bipolar mania

Two Phase 3 trials found symptom improvement by Day 3, sustained through Week 3; approval would add another adult use.

10 November 2026
Johnson & Johnson reports positive Phase 3 mania results for CAPLYTA

A second pivotal study found improvement in symptoms by Day 3; the findings will support a planned US regulatory submission.

8 September 2026
Johnson & Johnson to present neuropsychiatry data at Psych Congress 2026

24 abstracts at Psych Congress will report Phase 3 CAPLYTA data in bipolar mania, SPRAVATO analyses on anhedonia, seltorexant MDD+insomnia results, and LAI real‑world studies.